Development of an effective predictive screening tool for prostate cancer using the ClarityDX machine learning platform

The current prostate cancer (PCa) screen test, prostate-specific antigen (PSA), has a high sensitivity for PCa but low specificity for […]

March 2022

Includes: The PREVENT Study, Dr. Philip Barber bio, our first OPEN MIC NIGHT, PROpel Suggests Adding Olaparib to Abi-raterone Improves Outcomes, Risk vs. Benefit for Active Surveillance for Patients with Intermediate-Risk Disease, and more!